Results 81 to 90 of about 10,125,713 (289)

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges [PDF]

, 2020
International audienceNon-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action
Caussy, C., Loomba, Rohit, Loomba, R., Dufour, Jean-François, Dufour, J. F., Caussy, Cyrielle   +5 more
core   +2 more sources

Microbial Interventions in Processing of Plant Based Proteins: Unlocking Extraction Dynamics and Functionality for Human Health

Food Bioengineering, EarlyView.
Fermentation enhances nutritional & techno‐functional properties of plant protein. Three distinct stages of fermentation impact on different aspects of plant protein. Fermentation induces flavors modulation through new organic compounds formation. Plant protein fermentation improves their utility in food applications.
Disha, Mitali Madhumita, Dharmender Kumar, Pramod Kumar Prabhakar   +3 more
wiley   +1 more source

Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract

Zaporožskij Medicinskij Žurnal, 2017
The aim of this work is to investigate the direct markers of liver fibrosis (LF) in patients with steatohepatitis non-alcoholic and alcoholic origin in combination with obesity (OB) and pathology of the biliary tract (BT). Materials and Methods.
A. Yu. Filippova
doaj   +1 more source

The role of blood groups in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

, 2017
Introduction: Non-alcoholic fatty liver disease is defined as the accumulation of fat in the liver in the absence of excessive alcohol consumption or other known pathologies and is a spectrum of disease ranging from steatosis (fat infiltration into the ...
Arik, Ferhat, Gencer, Vedat, Gorkem, Hasan, Karaman, Hatice, Erden, ABDULSAMET, Kalan, Ugur, Karaman, Ahmet, Avci, Deniz, Karagoz, Hatice, Cetinkaya, Ali, Ozer, Ozerhan   +10 more
core   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Liraglutide for patients with non-alcoholic steatohepatitis [PDF]

The Lancet, 2016
2378 www.thelancet.com Vol 387 June 11, 2016 hepatic steatosis is due to weight loss? Previous studies have found a direct eff ect of weight loss on hepatic steatosis. In the LEAN study, the liraglutide effect did not remain signifi cant after adjusting for weight loss.
Gaborit, Benedicte, Darmon, Patrice, Ancel, Patricia, Dutour, Anne   +3 more
openaire   +4 more sources

Binary Bacillus subtilis protects the intestinal mucosa barrier and alleviates nonalcoholic steatohepatitis

Animal Models and Experimental Medicine
Background Nonalcoholic steatohepatitis (NASH) is characterized by liver steatosis, inflammation, and even fibrosis. NASH is likely to develop into cirrhosis and liver cancer, the major causes of liver related deaths.
Donglin Liu, Pengguo Chen
doaj   +1 more source

NASH: Non-Alcoholic Steatohepatitis [PDF]

, 2015
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol.
Heck, Jennifer
core